Find the latest pharmaceutical market place for formulations enquiry about Lansoprazole on PharmaCompass.com.

Tender// Various Finished Dosage Formulations needed in Bulgaria [ENA15837]

University Multiprofessional Hospital For Active Treatment - Dr. Georgi Stranski Ead is looking for supplies of Various Finished Dosage Formulations for commercial purposes. The deadline is 16-Jan-2023.
1. Lansoprazole (30 mg) Capsules. The required quantity is 360,000 units.
2. Haloperidol (1.5 mg) Tablets. The required quantity is 150,000 units.
3. Famotidine (20 mg) Injections. The required quantity is 120,000 units.
4. Omeprazole (40 mg) Injections. The required quantity is 120,000 units.

Reply

16 Dec 2022

Tender// Various Finished Dosage Formulations needed in Bulgaria [ENA15727]

Mnogoprofilna Bolnitsa Za Aktivno Lechenie - Pirdop Ad is looking for supplies of Various Finished Dosage Formulations for commercial purposes. The deadline is 3-Jan-2023.
1. Lansoprazole (30 mg) Tablets. The required quantity is 8,000 units.
2. Pentoxifylline (20 mg/ ml in 5 ml) Solution for Injections. The required quantity is 4,000 units.
3. Famotidine (20 mg) Tablets. The required quantity is 7,200 units.
4. Baclofen (10 mg) Tablets. The required quantity is 14,400 units.

Reply

03 Dec 2022

Tender// Various Finished Dosage Formulations needed in Croatia [ENA15076]

Psychiatrijska Bolnica Ugljan is looking for supplies of Various Finished Dosage Formulations for commercial purpose. The deadline is 25-Oct-2022.
1. Pantoprazole (20 mg) Gastro-Resistant Tablets. The required quantity is 18,000 units.
2. Lansoprazole (15 mg) Gastro-resistant Capsules. The required quantity is 2,500 units.
3. Gliclazide (60 mg) Prolonged-release Tablets. The required quantity is 4,500 units.
4. Vildagliptin (50 mg) Tablets. The required quantity is 1,500 units.

Reply

20 Sep 2022

Various Finished Dosage Formulations needed in Vietnam [ENA10193]

A company that is a leading provider of regulatory compliance products and services for the life sciences industry is looking for suppliers of Various Finished Dosage Formulations for commercial purposes. The required quantity is MOQ for each. The suppliers must support this enquiry with EU CTD Dossier.
1. Gliclazide (30 mg & 60 mg) Extended-release Tablets
2. Metformin (500 mg & 850 mg) Film-coated Tablets
3. Esomeprazole (40 mg) Enteric Coated Tablets
4. Esomeprazole (20 mg) Film-Coated Tablets
5. Lansoprazole (30 mg) Pellet Enteric Coated Capsules
6. Pantoprazole (20 mg & 40 mg) Enteric Coated Tablets
7. Rosuvastatin (10 mg, 5 mg & 20 mg) Film-Coated Tablets
8. Azithromycin (500 mg) Tablets
9. Clarithromycin (500 mg & 250 mg) Tablets
10. Alfuzosin (10 mg) Extended-Release Tablets

Reply

12 Apr 2021

United_States_of_America Flag

Looking for Dossiers of Lansoprazole (30 mg) Capsules [ENA08853]

A leading provider of regulatory compliance products and services for the life sciences industry based in the US is looking for suppliers of EU-CTD Dossiers of Lansoprazole (30 mg) Capsules for the market Vietnam, Cambodia, Indonesia, and Malaysia. The buyer will acquire EMA MA application dossiers and convert to ASEAN A-CTD format serving as the basis of their local application to register, manufacture and market Lansoprazole.

Reply

21 Oct 2020

Lansoprazole Orodispersible tablets needed in Hong Kong [ENA04374]

An integrated pharmaceutical trading company is looking for suppliers of Lansoprazole Orodispersible tablets. The required volume is about 28 tablets box (not less than 8,000 boxes in the first year). The suppliers must support with PIC/S standard formulation or GMP certified.

Reply

11 Jun 2019

Lansoprazole + Amoxicillin + Clarithromycin combination regimen needed in the UAE and GCC markets [ENA02781]

A speciality pharmaceutical company, established in Dubai with a clear focus on addressing several unmet medical needs in the GCC & MENA region is looking for suppliers of the triple regimen for Lansoprazole + Amoxicillin + Clarithromycin combination. Manufacturers must provide the following support for the product:
1. CEP/USDMF for the API
2. CPP issued from the country of origin
3. Zone IV stability data (A or B)
4. Bioequivalence Study data
5. e-CTD dossier

Reply

29 Nov 2018

Enquiry// Looking for Marketing Partners for various Finished Dose Formulations in China [ENA00365]

Inventia Healthcare, one of the leading drug delivery companies in India is searching for partners for its US FILED Products for the Chinese Market:

Products developed against international innovator:
1. Gliclazide 30/60 mg ER Tablets
2. Metformin HCl 500/750/1000 mg SR Tablets.
3. Lansoprazole 15/30 mg EC Capsules
4. Metoprolol 25/50/100/200 mg ER Tablets
5. Olmesartan Medoxomil 5/20/40 mg Tablets
6. Telmisartan 20/40/80 mg Tablets
7. Telmisartan + Hydrochlorthiazide 40/12.5, 80/12.5, 80/25 mg Tablets
8. Duloxetine 20/30/60 mg DR Capsules
9. Venlafaxine 37.5/75/150 mg SR Capsules
10. Darifenacin Hydrobromide 7.5/15 mg ER Tablets
11. Felodipine 2.5/5/10 mg ER Tablets
12. Rosuvastatin 5 /10/20/40 mg Tablets
13. Iloperidone 1/2/4/6/8/10/12 mg Tablets
14. Paliperidone 1.5/3/6/9 mg ER Tablets
15. Tolterodine Tartrate 2/4 mg ER Capsules

New Products Under development
1. Sitagliptin + Metformin 50/500 mg, 50/1000 mg Tablets
2. Sitagliptin + Metformin ER 50/500 mg, 50/1000; 100/1000 mg Tablets
3. Dapagliflozin 5/10 mg Tablets
4. Mesalamine 1.2 mg DR Tablets
5. Ezetimibe 10 mg Tablets
Interested partners can contact Sumeet Mehta at sumeet.mehta@inventiahealthcare.com or call +91-9930922062.

Reply

12 Jun 2017

Enquiry// Looking for Marketing Partners for various Finished Dose Formulations across Emerging Markets [ENA00236...

Inventia Healthcare, is searching for partners for:
DEVELOPED PRODUCTS
South East Asia, CIS, Australia, Middle East & Africa, LATAM:-
1. Lansoprazole 15/30 mg EC Capsules
2. Metoprolol 25/50/100/200 mg ER Tablets
3. Olmesartan Medoxomil 5, 20, 40 mg Tablets
4. Telmisartan 20/40/80 mg Tablets
5. Telmisartan + Hydrochlorthiazide 40/12.5, 80/12.5, 80/25 mg Tablets
6. Duloxetine 20/30/60 mg DR Capsules
7. Venlafaxine 37.5/75/150 mg SR Capsules
8. Darifenacin Hydrobromide 7.5/15 mg ER Tablets

South East Asia, CIS, Australia, Middle East & Africa, LATAM Argentina, Uruguay, Paraguay, Chile:-
1. Metformin HCl 750 mg SR Tablets

South East Asia, CIS, Australia, Middle East & Africa, LATAM, India:-
1. Gliclazide 30/60 mg ER Tablets
2. Felodipine 2.5/5/10 mg ER Tablets
3. Rosuvastatin 5 /10 /20/40 mg Tablets

Dossier for South East Asia, CIS, Australia Korea, Taiwan, China, Russia, Ukraine, Kazakhstan, Uzbekistan, Hong Kong, Thailand, Middle East & Africa, South Africa, GCC, Iraq, Algeria, LATAM, Argentina, Uruguay, Paraguay, Chile, India:-
1. Metformin HCl 500 mg SR Tablets

Dossier for South East Asia, CIS, Australia, Korea, Taiwan, China, Russia, Ukraine, Kazakhstan, Uzbekistan, Hong Kong, Thailand, Malaysia, LATAM, Argentina, Uruguay, Paraguay, Chile, All countries in SEA, CIS, Australia, Middle East & Africa:-
1. Metformin HCl 1000 mg SR Tablets
Interested partners can contact @ https://www.pharmacompass.com/api-manufacturers/inventia-healthcare-private-limited

Reply

02 Mar 2017

Enquiry//Esomeprazole, Omeprazole & Lansoprazole EU-CTD Dossiers with BE Studies needed for Indonesia [EN00400][E...

A subsidiary of the largest pharmaceutical company in Indonesia is searching for EU-CTD Dossiers with completed bio-equivalence (BE) studies for Esomeprazole tablets, Multiple Unit Pellets Systems (MUPS) - reference drug Nexium, Omeprazole Capsules & Lansoprazole Capsules.

Reply

27 May 2016